[go: up one dir, main page]

TN2009000142A1 - Bicyclic triazoles as protein kinase modulators - Google Patents

Bicyclic triazoles as protein kinase modulators

Info

Publication number
TN2009000142A1
TN2009000142A1 TNP2009000142A TN2009000142A TN2009000142A1 TN 2009000142 A1 TN2009000142 A1 TN 2009000142A1 TN P2009000142 A TNP2009000142 A TN P2009000142A TN 2009000142 A TN2009000142 A TN 2009000142A TN 2009000142 A1 TN2009000142 A1 TN 2009000142A1
Authority
TN
Tunisia
Prior art keywords
protein kinase
kinase modulators
bicyclic triazoles
triazoles
bicyclic
Prior art date
Application number
TNP2009000142A
Other languages
French (fr)
Inventor
Pierre-Yves Bounaud
Christopher Ronald Smith
Elizabeth Anne Jefferson
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of TN2009000142A1 publication Critical patent/TN2009000142A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present disclosure provides bicyclic triazole protein kinase modulators of formula I : and methods of using these compounds to treat diseases mediated by kinase activity.
TNP2009000142A 2006-10-23 2009-04-15 Bicyclic triazoles as protein kinase modulators TN2009000142A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87030906P 2006-12-15 2006-12-15
US91376607P 2007-04-24 2007-04-24
US95284007P 2007-07-30 2007-07-30
PCT/US2007/081841 WO2008051808A2 (en) 2006-10-23 2007-10-18 Bicyclic triazoles as protein kinase modulators

Publications (1)

Publication Number Publication Date
TN2009000142A1 true TN2009000142A1 (en) 2010-10-18

Family

ID=38956385

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000142A TN2009000142A1 (en) 2006-10-23 2009-04-15 Bicyclic triazoles as protein kinase modulators

Country Status (25)

Country Link
US (1) US8507489B2 (en)
EP (1) EP2084162B1 (en)
JP (1) JP5378222B2 (en)
KR (1) KR20090071612A (en)
AR (1) AR063520A1 (en)
AU (1) AU2007309149C1 (en)
BR (1) BRPI0717320A2 (en)
CA (1) CA2667428A1 (en)
CO (1) CO6190620A2 (en)
CR (1) CR10803A (en)
DK (1) DK2084162T3 (en)
EA (1) EA200970403A1 (en)
ES (1) ES2393130T3 (en)
IL (1) IL197958A0 (en)
MA (1) MA30871B1 (en)
MX (1) MX2009004059A (en)
NO (1) NO20091618L (en)
NZ (1) NZ575336A (en)
PE (1) PE20080893A1 (en)
PL (1) PL2084162T3 (en)
PT (1) PT2084162E (en)
SV (1) SV2009003235A (en)
TN (1) TN2009000142A1 (en)
TW (1) TW200835492A (en)
WO (1) WO2008051808A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (en) * 2007-08-09 2009-04-23 Sanofi Aventis NEW DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICATIONS, PHARMACEUTICAL COMPOSITIONS AND NEW MAIN USE AS MET INHIBITORS.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (en) 2008-08-14 2010-03-26 Takeda Pharmaceutical CMET INHIBITORS
EP2165710A1 (en) * 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
JP2012509342A (en) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド Substituted pyrrolo [2,3-B] -pyridine and -pyrazine
FR2941951B1 (en) * 2009-02-06 2011-04-01 Sanofi Aventis 6- (6-NH-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.
FR2941952B1 (en) * 2009-02-06 2011-04-01 Sanofi Aventis 6- (6-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) DERIVATIVES 5-FLUORO-BENZOTHIAZOLES AND 5-FLUORO-BENZIMIDAZOLES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.
FR2941950B1 (en) * 2009-02-06 2011-04-01 Sanofi Aventis 6- (6-O-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.
FR2941949B1 (en) * 2009-02-06 2011-04-01 Sanofi Aventis DERIVATIVES OF 6- (6-O-CYCLOALKYL OR 6-NH-CYCLOALKYL-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
WO2011079804A1 (en) 2009-12-31 2011-07-07 Hutchison Medipharma Limited Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (en) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc QUINASA FUSIONED BICYCLE INHIBITORS
AR085183A1 (en) * 2010-07-30 2013-09-18 Lilly Co Eli COMPOUND 6- (1-METHYL-1H-PIRAZOL-4-IL) -3- (2-METHYL-2H-INDAZOL-5-ILTIO) - [1,2,4] TRIAZOL [4,3-B] PIRIDAZINE, PHARMACEUTICAL COMPOSITION THAT UNDERSTAND AND USE IT TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT CANCER
UY33549A (en) * 2010-08-10 2012-01-31 Glaxo Group Ltd QUINOLIL AMINAS AS INHIBITING AGENTS OF KINASES
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (en) 2010-12-08 2012-07-04 中国科学院上海药物研究所 (1,2,4)-triazolo-(4,3-b) (1,2,4)-triazine compounds, as well as preparation method and use thereof
WO2012096929A2 (en) 2011-01-11 2012-07-19 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
CN103459396B (en) * 2011-02-10 2015-08-19 诺瓦提斯公司 As [1,2,4] triazolo [4,3-b] pyridazine compound of c-Met tyrosine kinase inhibitor
JP2014513724A (en) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ,エルエルシー Fusion bicyclic kinase inhibitor
CN103958509B (en) * 2011-09-15 2015-12-23 诺华股份有限公司 6-Substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-A]pyridine compounds as tyrosine kinase inhibitors
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013151913A1 (en) 2012-04-03 2013-10-10 Novartis Ag Tyrosine kinase inhibitor combinations and their use
RU2660354C2 (en) 2012-04-03 2018-07-05 Новартис Аг Combined products containing tyrosine kinase inhibitors and their use
CN103122000B (en) * 2012-09-03 2013-12-25 中美冠科生物技术(太仓)有限公司 High-selectivity c-Met kinase inhibitor used as antitumor drug
WO2014089904A1 (en) 2012-12-10 2014-06-19 Abbvie Inc. Triazinone compounds
US20150174034A1 (en) 2013-03-13 2015-06-25 Avon Products, Inc. Tyrosinase inhibitors
US20150152122A1 (en) * 2013-03-13 2015-06-04 Avon Products, Inc. Tyrosinase inhibitors
US9364405B2 (en) 2013-03-13 2016-06-14 Avon Products, Inc. Tyrosinase inhibitors
AR095365A1 (en) * 2013-03-13 2015-10-14 Hoffmann La Roche PROCEDURE TO PREPARE BENZOXAZEPINE COMPOUNDS
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
US9512121B2 (en) 2013-05-10 2016-12-06 Jiangsu Hansoh Pharmaceutical Co., Ltd. [1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof
US10301325B2 (en) 2015-09-24 2019-05-28 Shanghai Haiju Biological Technology Co., Ltd. Quinoline derivative, and pharmaceutical composition, preparation method and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
JPS60194443A (en) * 1984-03-16 1985-10-02 Fuji Photo Film Co Ltd Photosensitive silver halide material
EP0228061A3 (en) * 1985-12-23 1988-12-14 Takeda Chemical Industries, Ltd. Cephem compounds
JPS62228086A (en) * 1985-12-23 1987-10-06 Takeda Chem Ind Ltd Cephem compound
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2002083675A2 (en) * 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
WO2002083139A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
US7268136B2 (en) * 2002-12-18 2007-09-11 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
WO2006015124A2 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
SI1784396T1 (en) 2004-08-26 2011-03-31 Pfizer Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
KR100994173B1 (en) 2004-12-27 2010-11-15 알콘, 인코퍼레이티드 Aminopyrazine Analogues for Treatment of Glaucoma and Other Rho Kinase-Mediated Diseases

Also Published As

Publication number Publication date
EP2084162A2 (en) 2009-08-05
AU2007309149A1 (en) 2008-05-02
WO2008051808A3 (en) 2008-07-24
AU2007309149C1 (en) 2013-04-04
NZ575336A (en) 2012-04-27
PL2084162T3 (en) 2013-01-31
EP2084162B1 (en) 2012-09-12
CA2667428A1 (en) 2008-05-02
US8507489B2 (en) 2013-08-13
DK2084162T3 (en) 2012-10-01
AR063520A1 (en) 2009-01-28
SV2009003235A (en) 2009-10-15
JP2010507578A (en) 2010-03-11
BRPI0717320A2 (en) 2013-10-22
PT2084162E (en) 2012-10-09
CR10803A (en) 2009-06-16
KR20090071612A (en) 2009-07-01
WO2008051808A2 (en) 2008-05-02
NO20091618L (en) 2009-05-22
MX2009004059A (en) 2009-04-27
EA200970403A1 (en) 2009-10-30
TW200835492A (en) 2008-09-01
AU2007309149B2 (en) 2012-09-06
MA30871B1 (en) 2009-11-02
US20090258855A1 (en) 2009-10-15
IL197958A0 (en) 2009-12-24
CO6190620A2 (en) 2010-08-19
ES2393130T3 (en) 2012-12-18
PE20080893A1 (en) 2008-08-26
JP5378222B2 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
TN2009000142A1 (en) Bicyclic triazoles as protein kinase modulators
MX2009012623A (en) Heterocyclic kinase modulators.
TW200833692A (en) Triazolopyridazine protein kinase modulators
MX2009006706A (en) Bicyclic heterocyclic compounds as fgfr inhibitors.
UA104849C2 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as inhibitors of janus kinases
TW200745109A (en) Pyrrolo-pyridine kinase modulators
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
MX2009010984A (en) Fused ring heterocycle kinase modulators.
MX2009006704A (en) New compounds.
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
WO2008124849A3 (en) Pyrrolo-pyridine kinase modulators
WO2011115725A3 (en) Indazole compounds as kinase activity modulators for the treatment of cancer and related disorders
TNSN07028A1 (en) Fused ring heterocycle kinase modulators
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
IN2014DN07384A (en)
EA200870048A1 (en) Heteroaryl-PYRROLO [2,3-b] PYRIDINES AND PYRROLO [2,3-b] PYRMIDINES AS A INHIBITOR JANUS-KINASE INHIBITORS
IL193479A0 (en) Modulators of muscarinic receptors
MX2011006006A (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders.
TW200608960A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
UA101315C2 (en) Normal;heading 1;heading 2;heading 3;PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER
TW200608966A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
TW200734323A (en) 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2009126335A3 (en) Ant2 inhibitor compounds and methods of use thereof